BioNTech
An der Goldgrube 12
Mainz
D-55131
Germany
554 articles with BioNTech
-
COVID-19 would have claimed over 110,000 more lives in 2021 if vaccines weren't available, according to a Pfizer-sponsored report on the first year of the U.S. vaccination program.
-
Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
5/17/2022
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the U.S. Food and Drug Administration (FDA) expanded emergency use authorization (EUA) to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children 5 through 11 years of age.
-
Sofinnova Partners announced on Monday that it entered into a long-term strategic and financial partnership with Apollo to expand its presence in the life sciences.
-
BioNTech continues to build on the success of its mRNA COVID-19 vaccine and is rapidly expanding its investigational pipeline to include infectious diseases and oncology.
-
BioNTech Announces First Quarter Financial 2022 Results and Corporate Update
5/9/2022
BioNTech SE reported financial results for the three months ended March 31, 2022 and provided an update on its corporate progress.
-
Life Science industries are seeing massive financial fluctuations in how they're handling the COVID-19 pandemic, but there is some optimism of a recovery by biopharma executives.
-
Despite having infinitely better global communications, exact figures are hard to come by for COVID-19 fatalities. Here's a look at that story and more COVID-19 news.
-
Context Therapeutics' lead candidate ONA-XR prevents interaction between progesterone and its receptor, downregulates cancer stem cell mobilization and blocks immune evasion.
-
Three long-time FDA officials, Dr. Peter Marks, Dr. Janet Woodcock and Dr. Robert Califf wrote an op-ed in JAMA describing the reality that COVID-19 represents “the new normal.”
-
Pfizer reported first-quarter revenues of $25.7 billion, a whopping 82% operational growth. This growth was largely driven by its COVID-19 vaccine developed with BioNTech and its antiviral drug, Paxlovid.
-
BioNTech to Report First Quarter 2022 Financial Results and Operational Update on May 9, 2022
4/26/2022
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2022 on Monday, May 9th, 2022.
-
Moderna is poised to seek the regulatory authorization of its COVID-19 vaccine in children between six months and 5 years.
-
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
-
It was a very busy week for clinical trial news, with much of it coming out of the American Association of Cancer Research Annual Meeting. Read on for details.
-
Pfizer and BioNTech will submit updated data to the FDA to support the Emergency Use Authorization (EUA) of COVID-19 vaccination boosters in children between the age of 5 and 11.
-
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
4/14/2022
Pfizer Inc. and BioNTech SE announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age.
-
The FDA is looking at revising the current vaccine strategy and emphasizing that individuals need to consider their own risk tolerance. For that and more, continue reading.
-
The science community is aware of the effectiveness of the mRNA vaccines developed by Moderna and Pfizer-BioNTech. Now, they may be using that technology to treat cancer.
-
BioNTech Presents Positive Preliminary Phase 1/2 Data for First-in-Class CAR-T Program BNT211 at AACR
4/11/2022
BioNTech SE presented data from its ongoing first-in-human Phase 1/2 trial evaluating the safety and preliminary efficacy of the Company’s novel CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumors.
-
BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines
4/11/2022
BioNTech SE and Matinas BioPharma announced that they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and Matinas’ proprietary LNC platform technology.